全文获取类型
收费全文 | 22805篇 |
免费 | 1496篇 |
国内免费 | 455篇 |
专业分类
耳鼻咽喉 | 118篇 |
儿科学 | 395篇 |
妇产科学 | 300篇 |
基础医学 | 2982篇 |
口腔科学 | 322篇 |
临床医学 | 2919篇 |
内科学 | 4993篇 |
皮肤病学 | 625篇 |
神经病学 | 1005篇 |
特种医学 | 474篇 |
外国民族医学 | 1篇 |
外科学 | 1828篇 |
综合类 | 1579篇 |
现状与发展 | 2篇 |
一般理论 | 47篇 |
预防医学 | 3603篇 |
眼科学 | 366篇 |
药学 | 1395篇 |
25篇 | |
中国医学 | 541篇 |
肿瘤学 | 1236篇 |
出版年
2024年 | 64篇 |
2023年 | 2123篇 |
2022年 | 4490篇 |
2021年 | 6839篇 |
2020年 | 4482篇 |
2019年 | 281篇 |
2018年 | 260篇 |
2017年 | 217篇 |
2016年 | 233篇 |
2015年 | 253篇 |
2014年 | 410篇 |
2013年 | 427篇 |
2012年 | 323篇 |
2011年 | 417篇 |
2010年 | 365篇 |
2009年 | 347篇 |
2008年 | 333篇 |
2007年 | 346篇 |
2006年 | 337篇 |
2005年 | 283篇 |
2004年 | 281篇 |
2003年 | 253篇 |
2002年 | 176篇 |
2001年 | 162篇 |
2000年 | 127篇 |
1999年 | 114篇 |
1998年 | 94篇 |
1997年 | 72篇 |
1996年 | 84篇 |
1995年 | 47篇 |
1994年 | 32篇 |
1993年 | 52篇 |
1992年 | 40篇 |
1991年 | 49篇 |
1990年 | 30篇 |
1989年 | 24篇 |
1988年 | 19篇 |
1987年 | 20篇 |
1986年 | 7篇 |
1985年 | 45篇 |
1984年 | 40篇 |
1983年 | 25篇 |
1982年 | 24篇 |
1981年 | 24篇 |
1980年 | 16篇 |
1979年 | 13篇 |
1977年 | 10篇 |
1975年 | 10篇 |
1974年 | 6篇 |
1973年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 484 毫秒
81.
82.
《Transfusion and apheresis science》2020,59(4):102855
The activation of the innate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19. Pharmacological approaches have shown poor results in sepsis-like syndromes caused by the hypercytokinemia. Suppressing the cytokine storm is an important way to prevent the organ damage in patients with COVID-19. Extracorporeal blood purification could be proposed as an adjunctive therapy for sepsis, aiming to control the associated dysregulation of the immune system, which is known to protect organ functions. Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19. 相似文献
83.
84.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2020,32(6):347-353
The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-size-fits-all approach but recommend continual assessment of the situation with discussion within and between centres. 相似文献
85.
J. Alarcón-Rodríguez M. Fernández-Velilla A. Ureña-Vacas J.J. Martín-Pinacho J.A. Rigual-Bobillo A. Jaureguízar-Oriol L. Gorospe-Sarasúa 《Radiologia》2021,63(3):258-269
Most of the patients who overcome the SARS-CoV-2 infection do not present complications and do not require a specific follow-up, but a significant proportion (especially those with moderate / severe clinical forms of the disease) require clinicalradiological follow-up. Although there are hardly any references or clinical guidelines regarding the long-term follow-up of post-COVID-19 patients, radiological exams are being performed and monographic surveillance consultations are being set up in most of the hospitals to meet their needs. The purpose of this work is to share our experience in the management of the post-COVID-19 patient in two institutions thathave had a high incidence of COVID-19 and to propose general follow-uprecommendations from a clinical and radiological perspective. 相似文献
86.
87.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(11):720-723
Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia. 相似文献
88.
《Saudi Pharmaceutical Journal》2020,28(10):1243-1252
The novel coronavirus outbreak has reported to be rapidly spreading across the countries and becomes a foremost community health alarm. At present, no vaccine or specific drug is on hand for the treatment of this infectious disease. This review investigates the drugs, which are being evaluated and found to be effective against nCOVID-19 infection. A thorough literature search was performedon the recently published research papers in between January 2020 to May 2020, through various databases like “Science Direct”, “Google Scholar”, “PubMed”,“Medline”, “Web of Science”, and “World Health Organization (WHO)”. We reviewed and documented the information related with the current and future aspects for the management and cure of COVID-19. As of 21st July 2020 a total of 14,562,550 confirmed cases of coronavirus and 607,781 deaths have been reported world-wide. The main clinical feature of COVID-19 ranges from asymptomatic disease to mild lower respiratory tract illness to severe pneumonia, acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and death. The drugs at present used in COVID-19 patients and ongoing clinical trials focusing on drug repurposing of various therapeutic classes of drug e.g. antiviral, anti-inflammatory and/or immunomodulatory drugs along with adjuvant/supportive care. Many drugs on clinical trials shows effective results on preliminary scale and now used currently in patients. Adjuvant/supportive care therapy are used in patients to get the best results in order to minimize the short and long-term complications. However, further studies and clinical trials are needed on large scale of population to reach any firm conclusion in terms of its efficacy and safety. 相似文献
89.
《Journal of the American Medical Directors Association》2020,21(7):937-938
On February 20, 2020, a man living in the north of Italy was admitted to the emergency room with an atypical pneumonia that later proved to be COVID-19. This was the trigger of one of the most serious clusters of COVID-19 in the world, outside of China. Despite aggressive restraint and inhibition efforts, COVID-19 continues to increase, and the total number of infected patients in Italy is growing daily. After 6 weeks, the total number of patients reached 128,948 cases (April 5, 2020), with the higher case-fatality rate (15,887 deaths) dominated by old and very old patients.This sudden health emergency severely challenged the Italian Health System, in particular acute care hospitals and intensive care units. In 1 hospital, geriatric observation units were created, the experience of which can be extremely useful for European countries, the United States, and all countries that in the coming days will face a similar situation. 相似文献
90.